Small molecules that inhibit the Menin-MLL1 interaction provide promising therapeutic opportunities for acute leukemias with MLL1-r or NPM1c; several such small molecules, including DS-1594b, have entered clinical trials [41]. This evidence concerns the gene KMT2A and acute leukemia.